Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S

Marco Paciotti; Andrew L Schmidt; Praful Ravi; Rana R McKay; Quoc-Dien Trinh; Toni K Choueiri

doi:10.1002/onco.13736

Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S

Oncologist. 2021 May;26(5):e905-e906. doi: 10.1002/onco.13736. Epub 2021 Mar 24.

Authors

Marco Paciotti^{1

2}, Andrew L Schmidt³, Praful Ravi³, Rana R McKay⁴, Quoc-Dien Trinh¹, Toni K Choueiri³

Affiliations

¹ Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Department of Urology, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy.
³ Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
⁴ Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, California, USA.

Abstract

This letter to the editor outlines the use of stereotactic body radiotherapy for metastatic renal cell carcinoma in the U.S., identifying clinical predictors of utilization using the National Cancer Database.

Publication types

Letter

MeSH terms

Carcinoma, Renal Cell* / radiotherapy
Carcinoma, Renal Cell* / surgery
Humans
Kidney Neoplasms* / radiotherapy
Kidney Neoplasms* / surgery
Radiosurgery*